Best Life Sciences Companies in Edmonton, Canada
The 58 best Life Sciences companies in Edmonton, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Aurinia Pharmaceuticals.
Our analysis of 50 Life Sciences companies
$27.5b in tracked funding; 76% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Edmonton
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Aurinia Pharmaceuticals Developer of therapeutics for autoimmune diseases | $96M | 114 mo ago | Public | — | 1993 | Apple iCloud MailMicrosoft 365Zoho+16 | 111 patents Immunosuppressive therapies for lupus nephritis, including voclosporin and BAFF/APR dual inhibitors | — |
| 2 | OncoQuest Developing tumor antigen-specific monoclonal IgE antibodies for combinatorial immunotherapy | $69M | 76 mo ago | Series B | — | 2015 | — | 21 patents Targeted monoclonal antibody cancer therapies combined with immune adjuvants and delivery enhancers | — |
| 3 | Ceapro Developer of pharmaceutical and diagnostic products addressing unmet medical needs | $17M | 82 mo ago | Public | Gilles Gagnon President & CEO | 1997 | — | 63 patents Extraction, purification, and formulation of oat-derived beta‑glucan for nutraceutical and pharmaceutical applications | — |
| 4 | Future Fields Biomanufacturing unit for serum-free, bioactive growth factors, and other recombinant proteins 37Moat top 37%Funding top 39%Patents top 44%Tech top 49% All 9 signals ▾Moattop 37% Fundingtop 39% Patentstop 44% Techtop 49% Talentbottom 49% Innovationbottom 46% Marketbottom 42% Globalbottom 40% Newsbottom 18% Moat: Editorial + unicorn rating 7/10 · IP moat: 7 patents Funding: Raised $13.6M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $14M | 12 mo ago | Series A | Matt Anderson-Baron Chief Executive Officer | 2017 | Shogun Page BuilderCart FunctionalityShopify+23 | 7 patents Insect-based recombinant protein biomanufacturing and engineered insect production of target compounds | 1 job opening · 1 launch |
| 5 | DrugBank Drug database for life sciences and healthcare and clinical APIs | $9M | 51 mo ago | Seed | Craig Knox Co-Founder & CTO | 2006 | Apple iCloud MailGoogle WorkspaceRuby+29 | — | — |
| 6 | Pacylex Pharmaceuticals Developer of precision medicine to treat multiple cancers | $7M | 60 mo ago | Series A | Michael Weickert CEO | 2012 | WebflowreCAPTCHAHSTS+10 | 90 patents Oral N‑myristoyltransferase inhibitors for synthetic‑lethal cancer therapy | — |
| 7 | PanTHERA CryoSolutions Provider of a platform for cell cryopreservation | $6M | 65 mo ago | Acquired | Jason Acker Co-Founder | 2018 | WordPressPleskMySQL+17 | — | — |
| 8 | Tevosol Developer of portable warm perfusion devices | $5M | 83 mo ago | Seed | Jayan Nagendran Co-Founder and Chief Medical Officer | 2015 | — | 46 patents Ex vivo lung and heart ventilation, perfusion, and viability assessment technologies. | — |
| 9 | Metabolomic Technologies Developer of metabolomics-based diagnostics | $4M | 80 mo ago | Series A | Richard Fedorak Founder | 2014 | — | — | — |
| 10 | Radient Technologies Develops and markets high-value naturally derived plant extracts | $3M | 38 mo ago | Public | — | 2001 | — | 6 patents Extraction and purification of natural bioactive alkaloids for pharmaceutical use. | — |
| 11 | Northernmost Developer of medical device for organ preservation technology | $2M | 15 mo ago | Seed | Daniel Salamon Co-Founder & COO | 2022 | — | — | — |
| 12 | Rehabtronics Developer of rehabilitation devices for neurological diseases | $2M | 55 mo ago | Seed | — | 2003 | Cart FunctionalityWooCommerceWordPress+19 | 42 patents Therapeutic electrical muscle stimulation and pressure injury mitigation devices. | — |
| 13 | Fedora Pharma Canadian, early-stage biotech developing beta-lactamase inhibitors as combination therapy for MDR infections… | $200K | 14 mo ago | Seed | Christopher Micetich Founder | 2012 | — | — | — |
| 14 | IMBiotechnologies Manufacturer of embolotherapy products for the treatment of cancer | $129K | 14 mo ago | Seed | Irwin Griffith Co-Founder | 2008 | — | 19 patents Ultrasound‑activated embolic compositions for targeted vascular occlusion | — |
| 15 | Entos Pharmaceuticals Provider of nanotech-based drug delivery solutions | $100K | 13 mo ago | Series A | — | 2016 | GoDaddy Website BuilderGoogle MapsReact+11 | 53 patents Oncolytic viral therapies and SARS‑CoV‑2 nucleic‑acid vaccine platforms | 1 partnership |
| 16 | Rjhbiosciences Developer of transfection reagents and delivery systems | $100K | 79 mo ago | Funding Raised | Hasan Uludag CEO | 2016 | — | — | 1 launch · 1 partnership · 1 award |
Top 12 Life Sciences companies in Edmonton
#1
Series A · Edmonton, Alberta · founded 2017 · 40 employees$13.6Mraised▾
Biomanufacturing unit for serum-free, bioactive growth factors, and other recombinant proteins. The company has developed a platform called EntoEngine that assists in the production of serum-free medical products. They also offer various products and services related to recombinant proteins.
- Jun 2025Series A$8M
- Feb 2023Seed$11.2M
- Feb 2021Seed$2.2M
- Aug 2020Seed$150K
#2
Seed · Edmonton, Alberta · founded 2022$1.9Mraised▾
Developer of medical device for organ preservation technology. It offers a perfusion machine designed to preserve and transport kidneys for transplantation to improve patient outcomes and reducing wait times.
- Apr 2025Seed$1.9M
- Feb 2025Seed—
#3
Seed · Edmonton, Alberta · founded 2012 · 5 employees$200.1Kraised▾
Fedora Pharmaceuticals is a Canadian, early-stage biotech developing beta-lactamase inhibitors as a combination therapy for MDR infections. The company has developed a family of beta-lactamase inhibitors designed to have activity against pathogens. These novel beta-lactamase inhibitors used in combination with various beta-lactam antibiotics to treat those antibiotic infections currently resistant to therapy. β‑lactamases are enzymes produced by bacteria that destroy the antibiotic activity of β‑lactam antibiotics. It's lead candidate Nacubactam (FPI-1459) is in Phase I Clinical development and is being developed in partnership with F. Hoffmann la Roche and Meiji Seika Pharma. The company has 2 other candidates in preclinical stages. Apart from a licensing agreement with Roche in 2015 (USD 750M total potential payment), the company has also received a grant in 2017, from National Research Council of Canada’s Industrial Research Assistance Program (NRC-IRAP).
- Apr 2025Seed$895.1K
- Apr 2013Seed$200.1K
#4
Series A · Edmonton, Alberta · founded 2016 · 41 employees$100Kraised▾
Provider of nanotech-based drug delivery solutions. The company is focused on the development of next-generation nucleic acid-based therapies using their proprietary drug delivery system. The system uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells. The technology is applicable to a wide range of therapeutic types including gene therapy, mRNA, miRNA, RNAi, and CRISPR.
- May 2025Series A$1M
- Feb 2025Grant (prize money)$4M
- Oct 2020Grant (prize money)$5M
- May 2020Seed$100K
#5
Seed · Edmonton, Alberta · founded 2008 · 2 employees$128.8Kraised▾
IMBiotechnologies is a manufacturer of embolotherapy products for the treatment of cancer. The product developed called Ekobi is delivered through a catheter into the blood vessels that feed a target tissue and selectively block the tissue’s blood supply. The target tissue is either destroyed or devitalized, resulting in a therapeutic benefit. Ekobi 500 microspheres slowly degrade and are completely eliminated from the body in 4-6 months. These microspheres are easily detected using minimally invasive ultrasound. This product can be used against lung cancer, kidney cancer, etc.
- Apr 2025Seed$54K
- Jan 2025Seed$74.8K
#6
Public · Edmonton, Alberta · founded 1993 · 17 employees$95.9Mraised▾
Developer of therapeutics for autoimmune diseases. Its lead candidate voclosporin was developed for the treatment of lupus nephritis (LN). Other candidates includes AUR200 is a highly potent and specific immune modulator of BAFF and APRIL activity and AUR300 is a novel peptide therapeutic for autoimmune and fibrotic diseases.
- Dec 2016Post IPO$28.8M
- Aug 2016Post IPO$2.1M
- Jun 2016Post IPO$7.1M
- Feb 2014Post IPO$52M
#7
Series B · Edmonton, Alberta · founded 2015 · 9 employees$69Mraised▾
OncoQuest is a subsidiary of Quest PharmaTech and is a privately held, Canadian based pharmaceutical company focused on the development and commercialization of immunotherapies for cancer. OncoQuest's technology platform includes a panel of tumor antigen specific monoclonal immunoglobulins including CA125, MUC1, PSA and Her2/neu; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. OncoQuest's lead product, oregovomab, is currently undergoing a confirmatory phase IIb clinical trial involving 80 ovarian cancer patients in Italy and the United States. Additional clinical studies are underway or planned for oregovomab in combination with other therapeutic modalities for the treatment of pancreatic and ovarian cancers to identify optimal design for a product registration trial. OncoQuest's MUC1 program has already undergone a phase I clinical trial in breast cancer patients. OncoQuest's next-generation products are based on immunoglobulin E licensed from UCLA, Stanford University and Advanced Immune Therapeutics, Inc. These antigen-specific monoclonal IgE antibodies are currently in preclinical development. OncoQuest's current cli
- Mar 2020Series B$50M
- Feb 2018Series A$6M
- Nov 2015Series A$13M
#8
Public · Edmonton, Alberta · founded 2001 · 50 employees$2.6Mraised▾
Radient Technologies operates in the business of extraction, purification and isolation compounds, and ingredients from plants for use in the production of pharmaceutical intermediates, nutraceuticals, foods, and cosmetic products. The products include valerenic acid, flax SDG, and carnosic acid. Radient produces these high-value natural substances by uniquely combining MAP (Microwave Assisted Processing), a patented extraction technology and their knowledge in the downstream processing areas of purification and extraction.
- Apr 2023Post IPO$29.8K
- Jun 2022Post IPO—
- Dec 2021Post IPO$1.3M
- Oct 2020Post IPO—
#9
Seed · Edmonton, Alberta · founded 2006 · 81 employees$9Mraised▾
The company offers drug databases for clinical and academic research. It also offers a clinical API software that provides decision support and analytics based on the database.
- Apr 2022Seed$9M
- Oct 2020Seed—
#10
Public · Edmonton, Alberta · founded 1997 · 38 employees$16.6Mraised▾
Developer of pharmaceutical and diagnostic products addressing unmet medical needs. It focuses on natural-based active ingredients, including oat beta glucan, oat avenanthramides and oat oil. These ingredients are utilized in cosmeceuticals, nutraceuticals and pharmaceuticals. The company develops and commercializes its portfolio of products.
- Aug 2019Grant (prize money)$670.3K
- Sep 2016Grant (prize money)$250K
- Jul 2016Post IPO$7.7M
- Jul 2016Post IPO$5.7M
#11
Series A · Edmonton, Alberta · founded 2012 · 11 employees$7.2Mraised▾
Developer of precision medicine to treat multiple cancers. The drug candidate PCLX-001 is an orally bio-available small molecule that helps in N-myristoyl transferase inhibition, selectively kills cancer cells, and eliminates tumors. It helps in the treatment of lymphomas, solid tumors, leukemia, and other types of cancers.
- Jun 2021Series A$7.2M
#12
Acquired · Edmonton, Alberta · founded 2018 · 10 employees$6Mraised▾
PanTHERA Cryo provides technology for cryopreservation of cells tissues and organs. The company offers the patented small molecules ice crystal inhibitor (IRI) technology for maintaining cellular function at extended frozen storage and reduce the cell toxicity, stress, and formation of ice crystals. It reduces the use of DMSO, liquid nitrogen, and thawing of biological samples.
- Jan 2021Series A$4M
- Dec 2020Seed$2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Canada
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 990 Canada-affiliated papers.
- Ministry of Agriculture118
- Ministry of Education70
- University of Toronto61
- McGill University60
- Agriculture and Agri-Food Canada58
- Gene3→32
- Mutant2→13
- Genome2→12
- Transcription factor2→11
- Transcription (linguistics)1→9
- Gene2→40
- Fermentation1→12
- Antimicrobial1→9
- Population1→9
- Agriculture1→8
- Agriculture3→10
- Antibiotic resistance3→10
- Antimicrobial1→6
- Human health2→7
- Microbiome2→6
Where biotechnology is researched across Canada
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in Canada
Canada biotechnology patent filing is accelerating — 18,553 filings from 8,000 assignees (2016–2025), led by UNIV British Columbia, UNIV Health Network, NAT RES Council Canada; annual filings 1716→1734.
- UNIV British Columbia1570
- UNIV Health Network1208
- NAT RES Council Canada900
- UNIV Alberta753
- CA NAT Research Council699
- Medicago680
- UNIV Saskatchewan598
- Zymeworks594
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.